Seattle Genetics, Inc. (NASDAQ:SGEN) Weekly Ratings as of May 17, 2018

May 17, 2018 - By Lindsey Price

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.23 in 2017 Q4. It has change of 0.45, from 2017Q3’s 0.78. The ratio increased due to Seattle Genetics, Inc. positioning: 24 sold and 67 reduced. 44 funds acquired positions and 68 increased positions. Investors holded 140.23 million in 2017Q3 but now own 141.83 million shares or 1.14% more.
Tocqueville Asset Mngmt Ltd Partnership reported 27,065 shs. Platinum Invest Mngmt has invested 0.06% in Seattle Genetics, Inc. (NASDAQ:SGEN). Sumitomo Mitsui Asset Mgmt Co Limited holds 0% or 6,223 shs. Verition Fund Management Ltd Liability Company holds 0.02% or 4,622 shs. American Group Incorporated Inc holds 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 2,266 shs. Jpmorgan Chase And invested 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). Prudential Finance holds 0% or 6,091 shs. Wasatch Advsr Inc accumulated 0.69% or 979,393 shs. Baillie Gifford And invested in 14.96M shs or 1% of the stock. Pioneer Trust Retail Bank N A Or has invested 0.26% in Seattle Genetics, Inc. (NASDAQ:SGEN). Millennium Limited Co, a New York-based fund reported 334,921 shs. Qs Invsts Ltd Liability Com holds 0% or 3,511 shs. Pnc Group Incorporated owns 8,746 shs. Citadel Advisors Llc, Illinois-based fund reported 1.05M shs. Opus Point Prns Mngmt Ltd Liability Com holds 35,668 shs or 1.65% of its capital.

Seattle Genetics, Inc. had 10 selling transactions and 3 insider purchases since December 11, 2017. This’s net activity of $268.25 million. 5,000 shs were sold by HIMES VAUGHN B, worth $290,604. DRACHMAN JONATHAN G sold $552,452 worth of stock. $24.57 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shs were bought by BAKER BROS. ADVISORS LP. $951,393 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shs were sold by SIEGALL CLAY B.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Total analysts of 8 have positions in Seattle Genetics (NASDAQ:SGEN) as follows: 6 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 75%. Since January 31, 2018 according to StockzIntelligence Inc Seattle Genetics has 11 analyst reports. In Wednesday, February 14 report J.P. Morgan upgraded it to “Buy” rating and $66.0 target. On Wednesday, February 7 Needham maintained the shares of SGEN in report with “Buy” rating. On Friday, April 27 the stock has “Buy” rating by H.C. Wainwright. On Wednesday, February 7 Bank of America maintained Seattle Genetics, Inc. (NASDAQ:SGEN) with “Neutral” rating. On Wednesday, January 31 the rating was maintained by RBC Capital Markets with “Buy”. On Wednesday, March 21 Morgan Stanley maintained Seattle Genetics, Inc. (NASDAQ:SGEN) with “Overweight” rating. On Wednesday, February 7 the company was maintained by SunTrust. The company rating was maintained by H.C. Wainwright on Wednesday, February 7. On Wednesday, February 14 the company was upgraded by JP Morgan. On Tuesday, March 20 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by RBC Capital Markets. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $75.0 Maintain

The stock decreased 2.00% or $1.17 during the last trading session, reaching $57.33.Currently Seattle Genetics, Inc. is downtrending after 20.48% change in last May 17, 2017. SGEN has also 910,426 shares volume. SGEN underperformed by 32.03% the S&P 500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is worth $9.07 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

For more Seattle Genetics, Inc. (NASDAQ:SGEN) news published recently go to: Businesswire.com, Nasdaq.com, Streetinsider.com, Businesswire.com or Seekingalpha.com. The titles are as follows: “Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting” published on May 17, 2018, “Factors of Influence in 2018, Key Indicators and Opportunity within Patterson Companies, Zayo Group, Six Flags …” on May 09, 2018, “Seattle Genetics (SGEN) Announces Data Presentations at ASCO” with a publish date: May 17, 2018, “Seattle Genetics Appoints Roger D. Dansey, MD, Chief Medical Officer” and the last “Seattle Genetics (SGEN) Q1 2018 Results – Earnings Call Transcript” with publication date: April 27, 2018.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.